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A B S T R A C T
The 5′-hydroxymethyl metabolite of the penicillin based antibiotic flucloxacillin (FLX) is considered to be in-
volved in bile duct damage occurring in a small number of patients. Because 5′-hydroxymethyl FLX is difficult to
obtain by organic synthesis, biosynthesis using highly active and regioselective biocatalysts would be an al-
ternative approach. By screening an in-house library of Cytochrome P450 (CYP) BM3 mutants, mutant M11
L437E was identified as a regioselective enzyme with relatively high activity in production of 5′-hydroxymethyl
FLX as was confirmed by mass spectrometry and NMR. In contrast, incubation of M11 L437E and other mutants
with oxacillin (OX, which differs from FLX by a lack of aromatic halogens) resulted in formation of two me-
tabolites. In addition to 5′-hydroxymethyl OX we identified a product resulting from aromatic hydroxylation. In
silico studies of both FLX and OX with three CYP BM3 mutants revealed substrate binding poses allowing for 5′-
methyl hydroxylation, as well as binding poses with the aromatic moiety in the vicinity of the heme iron for
which the corresponding product of aromatic hydroxylation was not observed for FLX. Supported by the (dif-
ferences in) experimentally determined ratios of product formation for OX hydroxylation by M11 and its L437A
variant and M11 L437E, Molecular Dynamics simulations suggest that the preference of mutant M11 L437E to
bind FLX in its catalytically active pose over the other binding orientation contributes to its biocatalytic activity,
highlighting the benefit of studying effects of active-site mutations on possible alternative enzyme-substrate
binding poses in protein engineering.
1. Introduction
Flucloxacillin (FLX) is a synthetic antibiotic with the penicillin core
structure (Fig. 1A) and belongs to the class of penicillinase-resistant
isoxazolyl penicillins [1,2]. FLX is used in the treatment of Staphylo-
coccal infection. Its use is associated with rare cases of idiosyncratic
drug induced liver injury (IDILI, predominantly cholestatic), with a
higher incidence in women and elderly [3,4]. Because of its widespread
use FLX has been reported to be one of the most common causes of
severe and even fatal IDILI [5].
Although the mechanism of FLX-induced IDILI is not yet fully un-
derstood, it is accepted that certain polymorphisms of the immune
system, in particular HLA-B*5701, strongly increase the risk for IDILI
[6,7]. Although the association with HLA-B*5701 is one of the strongest
ever reported, only 0.1% of the patients with this genotype will even-
tually develop FLX-induced IDILI [6]. It is therefore likely that other
factors are involved in the susceptibility to cholestasis as well. Because
the metabolite of FLX appeared much more toxic to biliary epithelial
cells than FLX itself, variability in metabolism of FLX may also de-
termine susceptibility to FLX-induced DILI [8].
FLX is mainly metabolized by Cytochrome P450 (CYP) 3A4 to 5′-
hydroxymethyl FLX (Fig. 1B) [2]. To our knowledge, no synthetic route
for 5′-hydroxymethyl FLX has been published yet and only the use of
liver microsomes from rats treated with dexamethasone has been re-
ported as a method to obtain 5′-hydroxymethyl FLX at analytical scale
[8]. However, liver microsomes have intrinsically low activity of CYPs
and require animals as source of microsomes and are therefore less
suitable for biosynthetic approaches. As an alternative to liver micro-
somes, CYP BM3 (CYP102A1) from Bacillus megaterium has more per-
spective for biosynthesis, since it is the CYP with one of the highest
reported turnovers [9,10]. Whereas wild-type (WT) BM3 only accepts
long fatty acids as substrates, many successful protein engineering
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studies have been reported over the last years that report mutants of
BM3 able to hydroxylate drugs and drug-like compounds with high
activity and with regio- and/or stereo-selectivity [11–21]. However,
rationally predicting novel mutants with enhanced selectivity and/or
activity is still difficult especially when considering the flexibility of
their active site and because they can typically bind a variety of sub-
strates in multiple binding poses [18,22–26]. In the present combined
experimental and computational study we report and study the bioca-
talytic activity for (regioselective) 5′ methyl-hydroxylation of FLX by
CYP BM3 mutants M11, M11 L437E and M11 L437A. M11 is a mutant
capable of metabolizing a variety of drug-like or other industrially re-
levant substrates [25,27–29] and contains mutations R47L/E64G/F81I/
F87V/E143G/L188Q/Y198C/E267V/H285Y/G415S with respect to
wild-type BM3 [30]. Our in silico studies suggest that the L437E mu-
tation favors binding of FLX in its catalytically active binding pose over
substrate binding in a less reactive binding mode. This illustrates the
relevance to consider alternative enzyme-substrate binding poses as
well when designing promiscuous biocatalysts such as BM3 variants.
We could support these findings by incubations of M11 and its 437E
and 437A mutants with oxacillin (OX), which only differs from FLX by
the aromatic Cl and F substituents of the latter (Fig. 1).
2. Methods
2.1. Chemicals
FLX was kindly supplied by dr. Bayliss (University of Liverpool) and
OX was acquired from Sigma Aldrich (Zwijndrecht, the Netherlands;
purity: 99%). All other chemicals were obtained from standard sup-
pliers and of analytical grade.
2.2. Mutagenesis and expression of BM3 mutants
Mutant M11 L437A was cloned using the primers listed in Table 1
according to the quick change protocol as published previously [28].
Constructs for wild-type BM3 [31] and the BM3 mutants M01, M02,
M05, M11, M01 L437E, M11 L437E, M11 L437N, M11 L437S, M11
L437T [21], M01 S72D, M01 S72E, M01 A74D, M01 A74E [28], M01
S72I, M01 A82W, M11 S72D, M11 A82W V87F, M11 A82W L437N,
M11 V87F L437 N, M11 V87F L437S, M11 V87I L437N, M11 V87I
L437S [32], M11 V87A, M11 V87G, M11 V87H and M11 V87I [33]
have been reported before. Enzyme expression was conducted as de-
scribed in reference [28], except that after expression cells were lysed
with three rounds in an Avastin EmulsiFlex-C3 instead of a French
Press. In a next step, M11, M11 L437E and M11 L437A were purified
over Ni-NTA beads according to a protocol reported before [21]. En-
zyme concentrations were determined by CO-specs according to the
protocol of Omura and Sato [32].
2.3. Incubations
For biotransformation reactions, lysates containing 200 nM of BM3
mutants or 2mg/mL dexamethasone induced rat liver microsomes were
incubated with 250 μM FLX or OX in 100mM potassium phosphate
buffer pH 7.4 (KPi pH 7.4) in the presence of an NADPH-regenerating
system (NRS).
The NRS consisted of 100 μM NADP+, 10mM glucose-6-phosphate,
and 0.5 units/mL glucose-6-phosphate dehydrogenase. Reactions were
started by the addition of NRS and were performed at 24 °C for BM3 or
37 °C for rat liver microsomes. To compare the different BM3 mutants
in the initial screen, the incubations were performed for 1 h. For a se-
lection of BM3 mutants, enzyme kinetic parameters were determined by
incubating with different concentrations of FLX and OX. For enzyme
kinetic analysis, an incubation time of 10min was used during which
metabolite formation was found to be linear in time [data not shown].
The reaction was stopped by addition of an equal volume of ice-cold
methanol containing 2% acetic acid to prevent hydrolysis of the β-
lactam ring. Proteins were removed by centrifugation at 20,800g for
20min. The supernatant was analyzed by HPLC-UV and the identity of
the metabolites was confirmed by LC-MS. Michaelis-Menten parameters
were obtained by nonlinear regression using GraphPad Prism 5.00
(Graphpad Software, San Diego, CA, USA). Kinetics for M11 L437E and
M11 L437A were fitted to the Michaelis-Menten function, while M11
kinetics were fitted to the substrate inhibition function (with obtained
Ki = 4.0 mM) as described by Copeland in Eq. (5.44) of reference [33],
which assumes an inactive ternary substrate-enzyme-substrate (SES)
complex.
2.4. Preparative scale incubations
For preparative scale metabolite production, 100mL 100mM KPi
pH 7.4 containing 1 μM BM3, 2mM substrate and NRS was incubated at
Fig. 1. (A) Flucloxacillin (FLX). (B) 5′-hydroxymethyl FLX. (C) Oxacillin (OX).
Table 1
Forward (fw) and reverse (rv) primers used to mutate position L437. The introduced silent restriction site BsmA1 is
underlined and the mutated residues are highlighted in bold.
Sequence
L437A fw primer 5′-CTACGAGCTCGATATTAAAGAGACTGCTACGTTAAAACCTGAAGGCTTTGTGG-3′
L437A rv primer 5′-CCACAAAGCCTTCAGGTTTTAACGTAGCAGTCTCTTTAATATCGAGCTCGTAG-3′
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room temperature with constant agitation by a steering bean. For the
production of 5′-hydroxymethyl FLX, M11 L437E was used, whereas for
the hydroxylation of OX M11 was used. Fresh BM3 mutant and NRS
were added every hour for 7 h and once more after 20 h. The reaction
was terminated after 24 h by the addition of an equal volume ice-cold
methanol containing 2% acetic acid and centrifuged at 4600g for 2 h at
4 °C. Next, the methanol was evaporated and the sample concentrated
by vacuum centrifuging and the metabolites were purified from the
supernatant by preparative HPLC. 5′-hydroxymethyl-OX was identified
by 1H NMR and 5′-hydroxymethyl-FLX was identified by 1H and 19F
NMR. The aromatic hydroxylation of OX was identified by LC-MS/MS.
2.5. Analytical methods
Metabolite formation for FLX and OX was assessed on a Shimadzu
HPLC equipped with two LC-20AD pumps, an SPD20A UV-detector set
to 272 nm, and a SIL20AC auto-sampler. Separation was performed on a
Luna 5 μm 4.6× 150mm C-18 column with a binary gradient con-
sisting of eluents A (0.1 v/v% formic acid, 1 v/v% acetonitrile and
98.9 v/v% H2O) and B (0.1 v/v% formic acid, 98.9 v/v% acetonitrile
and 1 v/v% H2O) at 0.5mL/min. The gradient went from 40 v/v% to
99 v/v% B in 23.5min, after which the percentage went back to 40% B
in 0.5 min. The column was equilibrated for 11min before a next
sample was injected.
An Agilent 1200 rapid resolution LC system connected to an Agilent
TOF 6230 mass spectrometer with an electrospray ionization source
was used to determine the mass of the metabolites. 3500 V 10 L/min
nitrogen drying gas together with 50 psig nitrogen nebulizing gas at
350 °C were used and the capillary was set to 3500 V. For MS/MS an
Agilent QTOF 6500 was used with a collision energy of 10 V. The LC
column and gradient were identical to the HPLC-UV set-up.
2.6. Preparative HPLC
The preparative HPLC system was similar to the one described
above, but with a Shimadzu LC-20AB pump and a FRC-10A fraction
collector connected. Samples consisting of 1mL sample were injected
into an Xbridge prep C18-MS (5 μm 10×50mm). The same eluents as
described above were used in a binary gradient going from 25% to 50%
eluent B in 11min for FLX, and from 20% to 50% eluent B for OX. Then
it went back to the starting conditions and equilibrated again for
4.5 min. The flow rate was 3mL/min. Afterwards the collected fractions
were evaporated to dryness and stored at −20 °C.
2.7. 19F and 1H NMR spectroscopy
NMR spectra for FLX, OX and their metabolites were measured in
deuterated DMSO‑d6 (Sigma Aldrich, Zwijndrecht, Netherlands) on a
Bruker Avance 500 (Fallanden, Switzerland) at room temperature,
equipped with a cryoprobe operating at 500.13MHz. For identification
of FLX metabolites, 19F spectra and 1H of FLX were compared to Keun
et al. [34]
2.8. Dissociation constant measurements
To determine dissociation constants of the binding of FLX and 5′-
hydroxymethyl FLX to BM3 mutants, binding spectra of the substrate-
protein and metabolite-protein complexes were acquired as published
previously [21]. The compounds were titrated into a cuvette containing
1mL of 100mM KPi pH 7.4 and 1 μM BM3 up to a final additional
volume of not more than 2% of the initial solution volume. UV/Vis
difference spectra were obtained on a Shimadzu UV-250IP spectro-
photometer (Shimadzu Duisburg, Germany) at 24 °C. The substrate-free
sample was subtracted from all following acquired spectra. The differ-
ence in absorption between 422 nm and 390 nm was plotted and ana-
lyzed by nonlinear regression fitting the data to the one site – specific
binding with hill slope function of GraphPad Prism 5.00 (Graphpad
Software, San Diego, CA, USA) to obtain the reported KD values.
2.9. Molecular docking
The heme domain of mutant BM3 M11 was modelled using chain B
of the M11 crystal structure (PDB ID 5E9Z) [26]. Missing residue Q73
and missing atoms of residues K31, Q73, K94, K97, Q109, Q110, D136,
K187, K218, Q229, T245, R255, Q288, K306, K449 were added with
Modeller 9.3 [35]. The structure was then steepest-descent energy
minimized and protonated using the Reduce tool from the AmberTools
package [36]. The protonated M11 structure was used as a docking
template for FLX and OX.
FLX was first energy minimized according to the MMFF94 force
field [37] with Open Babel 2.3.9 [38]. Partial atomic charges for FLX
for use in MD were obtained with GAMESS (version 1 May 2012) [39]
at the Hartree-Fock level using the 6-31G* basis set. Subsequently, the
structure was energy minimized at the B3LYP/COSMO/6-31G* level of
theory. An initial molecular structure of OX was obtained from the
energy minimized FLX structure by replacing the fluorine and chlorine
by hydrogens. OX was subsequently energy minimized according to the
MMFF94 force field [37] with Open Babel 2.3.9 [38] as well.
The protein template and energy minimized FLX or OX structures
were used in flexible docking using Protein-Ligand Ant System
(PLANTS) [40] version 1.2 and the PLANTS ChemPLP scoring function
[41]. To determine flexible residues, an alignment was made of the four
chains of the 5E9Z crystal structure (Chains A, B, C and D) using
Maestro 9.3.5 (Schrödinger Suite 2012.2) [42]. The side chains of six
residues (Q73, L181, Q188, Q403, L437 and T438) were treated flexible
during docking. The center of docking was placed in the middle of the
active site with a distance of 0.68 nm from the heme iron along the
vector connecting the heme iron with the coordinating sulfur atom of
C458. The docking radius was set as 1.5 nm from the center of the
docking sphere. The 300 highest-ranked docked structures were re-
tained. Based on visual inspection, two types of binding poses were
identified, designated as poses 1 and 2, respectively (see Results and
discussion section). From both types of binding modes, 4–6 FLX binding
poses (with the substrate's amide bond in trans conformation) were
selected based on visual inspection and used as starting structures for
separate MD simulations (50 ns production, see below for settings). For
every combination of mutant and type of pose, the simulation with
lowest root-mean-square deviation (RMSD) of the ligand heavy-atom
positions with respect to the MD starting structure was identified as the
most stable one, and this simulation was used for further analyses.
2.10. Molecular Dynamics (MD) simulations
Mutations on position 437 were introduced into the crystal structure
of the M11 heme domain [26] with Modeller version 9.3 [35], after
which two residues on each site of the mutated residue were allowed to
reorganize in order to reduce possible steric clashes. Partial charges for
the substrate atoms were obtained as described above and other in-
teraction parameters for FLX were used from the General Amber Force
Field [43], obtained by using Antechamber version 1.27 [44]. Gromacs
version 5.1.1 was used for all simulations [45]. The Amber99SB-ILDN
force field [46] was used to describe the protein. Unless noted other-
wise, results are presented and discussed for simulations with the heme
moiety in its penta-coordinated resting state. In addition, simulations
with the heme modelled as Compound I (Cpd I) were performed in
which the ferryl oxygen atom was placed along the normal to the heme
plane at a distance of 0.164 nm from the iron atom. To describe both
the heme resting-state and Cpd I, force field parameters were employed
from reference [47].
Every complex was solvated in a dodecahedral box with approxi-
mately 14,500 TIP3P water molecules [48] and 14 sodium ions (15
sodium ions for M11 437E simulations) were added to neutralize the
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charge of the systems. The systems were energy minimized (steepest-
descent) and heated up to 300 K in three 250 ps NVT simulations at 100,
200 and 300 K, in which protein-backbone Cα atoms were positionally
restrained with harmonic potentials with force constants of 10,000,
5000, and 50 kJ nm−2 mol−1, respectively. Afterwards, 50.25 ns of
(unrestrained) NpT simulations were carried out at 1 atm and 300 K.
The first 0.25 ns of these production runs were discarded for further
analyses. A time step of 2 fs was used, and bond lengths involving hy-
drogen atoms were constrained using the LINCS algorithm, with the
highest order in the expansion of the constraint coupling matrix set to 4
[49]. A Langevin integrator was used with the friction coefficient for
each particle calculated as mass/0.1 ps. A Berendsen barostat [50] was
used to maintain the pressure close to its reference value during NpT
simulations, with a coupling time of 0.5 ps and an isothermal com-
pressibility of 4.5× 10−5 bar−1. Van der Waals and short-range elec-
trostatic interactions were explicitly evaluated every time step for pairs
of atoms within 0.9 nm of each other, using a grid-based pairlist that
was updated every five time steps. Long-range electrostatic interactions
were calculated every time step, according to the smooth particle mesh
Ewald method [51] with a grid spacing of 0.125 nm. Linear center of
mass motion removal took place every 5 time steps. All simulations
were performed twice, in independent runs that started with different
randomly assigned atomic velocities. Atomic positions and energies
were stored every 2 ps for further analyses. Snapshot images were made
with VMD (version 1.9.2) [52]. RMSDs in atomic positions were de-
termined with respect to MD starting poses, and interatomic distance
and RMSD time series were plotted with matplotlib, with running
averages over 200 ps. Interaction profiles between ligands and the
mutants were analyzed in terms of protein-ligand interaction fre-
quencies using an in-house Python script to identify interaction types,
using rule-based protocols described in the supplementary information
of reference [53].
3. Results and discussion
3.1. Identification of catalytically active BM3 mutants
To identify BM3 mutants that can serve as a biocatalyst for the
synthesis of 5′-hydroxymethyl FLX, first the activity screening of an in-
house library of BM3 mutants was performed (see Fig. S1 of the
Supplementary Information) [27,54]. For all active mutants tested only
one metabolite was found with m/z of 470.1 [M+H]+ corresponding
with hydroxylation of FLX (Fig. S2A). Using 19F and 1H spectra NMR
this metabolite was identified as 5′-hydroxymethyl FLX. The spectra
obtained (Fig. S3 and S4) were consistent to the 19F and 1H spectra
reported previously by Keun et al. [34] From our library screening (Fig.
S1), mutant M11 L437E was identified as the most active mutant for
FLX conversion. Enzyme kinetic analysis showed similar Vmax values for
M11 L437E and its parent M11 mutant (Fig. 2, Table 2) but M11
displayed a decrease in activity at higher substrate concentrations in-
dicating substrate inhibition and formation of an inactive SES complex
[33]. UV/Vis binding studies of M11 L437E showed a higher KD value
when compared to M11 (Table 3, Fig. S5) and an H-coefficient higher
than 1 indicating positive cooperativity, which was not observed for
M11. For another M11 437 mutant, M11 L437A, we found a similar KD
value but a lower Vmax value when compared to M11 L437E, Fig. 2 and
Tables 2 and 3. The values for and trends in the kinetically determined
Km of the BM3 mutants differ significantly from those observed for KD
in our binding measurements, Tables 2 and 3. Assuming that binding
and unbinding constants k1 and k−1 are the same, this suggests that the
catalytic constant k2 may be much larger than k−1. It should be realized
however that Km is determined based on the concentration-dependence
of the enzyme reaction in which the iron atom is in a Fe2+-state and
interacts with an oxygen atom, while KD is determined based on the
concentration-dependence of the spin-state of the enzyme in which the
iron is in a Fe3+-state. Differences between Km and KD (of up to 50–100
fold) have been reported previously for other CYP enzymes as well
[55].
Interestingly, after incubating OX with the M11, M11 L437E and
M11 L437A mutants, two different metabolites were observed, both
with the predicted m/z of 418.1 [M+H]+ (Fig. S2B). 1H NMR analysis
showed that one of the metabolites was the 5′-hydroxymethyl meta-
bolite, cf. Fig. S6. The second metabolite was identified by MS/MS as a
product of aromatic hydroxylation: the characteristic fragment of m/z
243 caused by fragmentation of the β-lactam ring [56] increased in
mass by m/z 16 upon hydroxylation, while the second fragment with an
m/z of 160 did not (Fig. S7). This indicates that the incorporated
oxygen atom is located at the aromatic ring of OX. Fig. 3 shows that
introducing the glutamate mutation at the distant active-site position
437 leads to a reduction of total OX conversion. At low substrate con-
centrations we did not observe a decrease in product formation for FLX
upon introducing the L437E mutation, Fig. 2. In the remainder we
performed protein-structure based modeling and MD simulations to
obtain more insight into the effects of the 437E mutation on substrate
binding and conversion.
3.2. Substrate docking
Docking revealed two major binding poses of FLX with a CeH bond
carbon atom within 0.6 nm of the heme iron, which was previously
used as cut-off to identify possible catalytically-active binding or-
ientations [57]. When docking FLX into the M11 binding pocket, 11%
of the docked poses was found with the 5′ methyl carbon atom within
0.6 nm of the heme iron, whereas in 30% of the poses the phenyl ring of
FLX was found to be in closest proximity of the heme iron. These two
Fig. 2. Michaelis-Menten kinetics for M11 (circles), M11 L437E (triangles) and
M11 L437A (squares). Data depict the mean of one experiment performed in
duplo (± SD).
Table 2
Michaelis-Menten parameters Vmax and Km as obtained for the metabolism of
FLX to 5′-hydroxymethyl flucloxacillin by BM3 mutants M11, M11 L437E and
M11 L437A, and substrate inhibition constant Ki for M11.
Vmax (nmol product/min/nmol CYP) Km (μM) Ki (mM)
M11 11.0 ± 1.9 307 ± 104 4.0 ± 0.2
M11 L437E 10.5 ± 0.5 404 ± 82 –
M11 L437A 6.2 ± 0.6 922 ± 270 –
Table 3
UV/Vis determined dissociation constants KD and H-coefficients for the binding
of FLX to BM3 mutants M11, M11 L437E and M11 L437A.
KD (μM) H-coefficient
M11 18.6 ± 4.0 1.1 ± 0.3
M11 L437E 36.9 ± 1.6 1.7 ± 0.1
M11 L437A 34.7 ± 4.8 1.0 ± 0.1
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types of binding poses are in the remainder designated as binding pose
1 and 2, respectively, and used as starting points of our MD simulations
of FLX in M11, M11 L437A and M11 L437E. Similar results were ob-
tained when docking OX in M11. In 13% of the docked poses the 5′
methyl carbon atom of OX was within 0.6 nm of the heme iron, and in
30% of the OX binding modes the phenyl ring was closest to the heme
iron.
Binding of FLX in pose 1 can lead to 5′-methyl hydroxylation, since
this methyl group is in close contact with the heme iron (cf. Fig. 4A and
B). In pose 2, the aromatic para‑carbon atom is typically in closest vi-
cinity of the heme iron, Fig. 4C. The FLX halogens at meta-position from
this carbon can have a detrimental effect on intrinsic reactivity, in line
with results from QM studies by Bathelt et al. on the effects of (single)
halogen substituents on CeH bond activation showing an increase of
several kJ/mol per meta halogen substitution [58]. This can explain our
finding that in contrast to OX, no aromatic hydroxylation was observed
for FLX, also when considering that docking results for pose 2 only
show small differences in the distributions of CeFe distances between
OX and FLX (Fig. S8), suggesting that steric hindrance due to the
halogen groups is not on the basis of a lack of aromatic hydroxylation of
FLX upon binding in pose 2.
3.3. Molecular Dynamics simulations
MD simulations starting from pose 1 showed only small fluctuations
in the relatively low RMSD of the heavy-atom positions of the substrate
in the M11 and M11 L347E simulations and in one of the M11 L437A
simulations (Fig. 5A). Together with our finding that the distance be-
tween the 5′ methyl carbon site-of-metabolism and Fe is constantly well
below 0.6 nm in simulation (Fig. 6A), this indicates that pose 1 is stable
in the mutants. Binding pose 1 was also found to be stable in the si-
mulations with the heme group modelled as Cpd I, with average dis-
tances between a (i.e., the closest) 5′ methyl hydrogen and the ferryl
oxygen of less than 0.3 nm and average angles of approach of this
methyl hydrogen to Fe]O on the order of 120 degrees, respectively
(Supplemental Table S1). These values are close to typical values re-
ported for transition states for CYP mediated aliphatic hydroxylation
[59,60]. Table S1 also shows that no significant differences were found
among the different mutants, suggesting that differences in binding
orientation and CeH bond activation energy are not on the basis of the
observed trends in FLX conversion rates described in Section 3.1.
As can be seen from protein residue-ligand interaction profiles ob-
tained from MD (Figs. S9–S12), FLX is engaged in more and/or more
frequent polar interactions with M11 L437E when compared to M11 or
M11 L437A. In the L437E mutant, the COO– moiety of FLX shows an-
ionic hydrogen bonding to both the S72 and S332 residues during MD
(Figs. 4B, 7A, 7B, S10), whereas only one of these interactions is formed
during simulations of the other mutants (Figs. 4A, 7A, 7B, S9, S11).
Note that in one of the M11 L437E simulations a Ser-COO-interaction
was lost after 25 ns but a third independent MD simulation additionally
confirmed the possibility of FLX interacting with both serines, Fig. S12.
Another interaction between FLX and M11 L437E which was not ob-
served in the M11 and M11 L437A simulations involved K69 interacting
with the beta-lactam oxygen of FLX (Figs. S9–S12)·The simultaneous
interaction between the FLX COO– group and S72 and S332 and the
interaction with K69 may be induced by repulsion between the sub-
strate's and E437’s anionic groups, as suggested by the small change in
binding orientation towards S332 in M11 L437E with respect to M11
(Fig. 4A and B) and by the substrate-binding induced interaction be-
tween E437 and Q188 (Figs. 7C and 4B). Whereas the anionic repulsion
can negatively affect total FLX binding to M11 L437E when compared
Fig. 3. Oxacillin metabolite formation by BM3 mutants M11, M11 L437A and
M11 L437E. White bars depict aromatic hydroxylation of oxacillin and black
bars depict 5′-hydroxymethyl oxacillin formation. Total metabolite formation of
M11 is set to 100% and the data show the mean (± SD) for one experiment
performed in duplo.
Fig. 4. Binding orientations of FLX (in green) observed during MD. Heme group (yellow) and residues S72, Q188, L/E437 and S332 (yellow) are explicitly shown in
stick representation as well. Selected interactions/contacts are represented with dashed lines. (A) Representative FLX binding pose 1 in M11. Interactions/contacts
depicted are between FLX′ 5′ methyl carbon and the heme iron, and between a FLX′ carboxyl oxygen and the S72 side-chain hydroxyl group. (B) Representative FLX
binding pose 1 in M11 L437E, interactions/contacts depicted are between FLX′ carboxyl oxygens and S332's backbone nitrogen or S332's and S72's side-chain
hydroxyl groups, and between the E437 carboxyl oxygens and Q188 nitrogen. (C) FLX binding pose 2 in M11 L437E, interactions/contacts depicted are between FLX′
phenyl para-carbon and heme iron, between E437's carboxyl and FLX' ring oxygen, and between FLX′ lactam oxygen and S72's side-chain hydroxyl group.
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to M11 or M11 L437A, the observed interaction with S72, S332 and
K69 will have a stabilizing effect on substrate binding in pose 1 in the
L437E mutant.
The stabilizing hydrogen bonds of FLX with S332 and K69 in the
L437E mutant are not observed when simulating FLX in binding pose 2
(Fig. 4C and S14). A hydrogen bond between the S72 side-chain OH
group and the lactam oxygen of FLX is present during simulation in
M11 and in the L437A and L437E mutants, cf. Fig. 4C and Figs.
S13–S15. Also another hydrogen bond is formed between Y51 and the
FLX COO-group in all simulations involving binding pose 2 (Figs.
S13–S15) except in one of the runs in M11 L437E (Fig. S14B). Simu-
lations starting from binding pose 2 show a higher substrate RMSD and
larger fluctuations of the RMSD (Fig. 5B) in M11 L437E than in M11
and one run of M11 L437A. This suggests that the L437E mutation
destabilizes binding pose 2, as supported by the large fluctuation in the
distance between the heme iron and aromatic para carbon in the M11
L437E simulations, Fig. 6B. Destabilization of pose 2 in L437E can be
due to electrostatically unfavorable contacts between E437's anionic
group and the partially negatively charged oxygen and nitrogen atoms
in the central 5-ring of FLX (Fig. 4C), in line with higher average pro-
tein-substrate electrostatic interaction energies obtained for pose 2
binding to M11 L437E when compared to results from simulations in
M11 and M11 L437A, Table 4. For M11 and M11 L437A, favoring
factors for FLX binding in pose 1 over pose 2 were not observed.
Based on these findings we hypothesize that M11 L437E preferably
binds FLX in pose 1 and that pose 2 may contribute more substantially
to M11 and M11 L437A binding. Since no aromatic site-of-metabolism
(SOM) was identified for FLX, binding in pose 2 can have a detrimental
and inhibitory effect on metabolite formation for this substrate. Our
suggestion that this effect is a result of low intrinsic reactivity, and not
due to possible hindrance for transition state formation by the halogen
substituents (Section 3.2) is supported by our Cpd I simulations with
FLX bound in pose 2. In M11 L437A and in one of the simulations of
M11 and M11 L437E, the para carbon was found to be able to adapt an
Fig. 5. Time series of heavy-atom positional root-
mean-square deviations (RMSDs) of FLX in BM3
mutants M11 (red), M11 L437E (blue) and M11
L437A (yellow), as obtained from MD simulations
starting from binding pose 1 (A) or binding pose 2
(B). Results from independent MD simulations per
system are shown by solid and dotted lines, respec-
tively.
Fig. 6. Time series during MD simulations of FLX in
M11 (red), M11 L437E (blue) and M11 L437A
(yellow) for the distance between FLX 5′-methyl
carbon atom and the heme iron as obtained from MD
simulations starting from binding pose 1 (A), and for
the distance between the heme iron and the FLX
carbon atom at para position (meta position with
respect to the aromatic halogen substituents) as ob-
tained from MD simulations starting from binding
pose 2 (B). Results from independent MD simulations
per system are shown by solid and dotted lines, re-
spectively.
Fig. 7. Time series during MD simulations of FLX in M11 (red), M11 L437E (blue) and M11 L437A (yellow) for the minimum distance between FLX' carboxylate
carbon atom and Ser72 atoms (A), and for the minimum distance between FLX' carboxylate carbon atom and Ser332 atoms (B); and time series during MD
simulations of M11 437E in complex with FLX in pose 1 (light blue) or 2 (dark blue), or without substrate (green), for the distance between Q188's nitrogen atom and
E437's carboxylate carbon atom (C).
Table 4
Average FLX-protein electrostatic interaction energies (in kJ/mol) as obtained
from MD simulations of BM3 mutants M11, M11 L437A and M11 L437E in
complex with FLX binding in pose 1 or pose 2.
M11 M11 L437A M11 L437E
Pose 1 −73.3 −72.0 −200.1
Pose 2 −86.7 −94.7 −71.2
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average distance to the ferryl oxygen which was between 0.3 and
0.4 nm, Table S2. This was previously used as criterion to select protein-
substrate structures in combined quantum mechanical/molecular me-
chanical studies on transition state formation for aromatic CeH hy-
droxylation [59,60]. The possible inhibitory effect of a non-reactive
binding pose was recently also described for another biocatalytic active
CYP in X-ray crystallographic studies on CYP109E1 by Thunissen and
co-workers [61]. Considering the similar binding modes obtained for
OX and FLX, our hypothesis is supported by comparing ratios in product
formation for OX conversion among the mutants, for which M11 and
M11 L437A showed approximately 5-fold more aromatic hydroxylation
than M11 L437E, Fig. 3.
4. Conclusions
We performed a combined computational and experimental study
on selective 5′-methyl hydroxylation of FLX by CYP BM3 mutants M11,
M11 L437E and M11 L437A. At substrate concentration on the order of
its observed Km value, we found comparable activity in FLX hydro-
xylation by CYP BM3 mutants M11 L437E and M11, but more product
formation by M11 for the similar OX substrate. In line with the ob-
served differences in product ratios for OX, our MD simulations suggest
a preference for substrate binding by M11 L437E in an orientation
consistent with 5′ methyl hydroxylation over an alternative binding
mode. FLX binding in the latter orientation may well have a detrimental
effect on product formation by M11 and M11 L437A, illustrating the
relevance and potential for enzyme engineering in considering possible
catalytically inactive poses as well in the prediction and fine tuning of
substrate binding and conversion by malleable biocatalysts. Our simu-
lation data could not explain the basis for substrate inhibition at higher
substrate concentration as observed for M11 but not for M11 L437E and
M11 L437A. Considering the relatively high activity of M11 L437E for
5′-hydroxylation of FLX it can serve as an alternative to biosynthesize
5′-hydroxymethyl FLX compared to the currently available approach
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